Metronomic chemotherapy: Back to the future!

Nicolas André, Laetitia Padovani, Arnauld Verschuur
{"title":"Metronomic chemotherapy: Back to the future!","authors":"Nicolas André,&nbsp;Laetitia Padovani,&nbsp;Arnauld Verschuur","doi":"10.1358/dnp.2010.23.2.1475913","DOIUrl":null,"url":null,"abstract":"<p><p>Angiogenesis is crucial for the growth of cancer. As such, it has become an established target to fight cancer. Metronomic chemotherapy-the chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule of administration, at close regular intervals, with no prolonged drug-free breaks-is a potential approach to control advanced cancer disease. It is thought to work primarily through antiangiogenic mechanisms and has the property to kill resistant cancer cells and/or to inhibit tumor growth while significantly reducing undesirable toxic side effects. Here, we will discuss potential mechanisms of action of metronomic chemotherapy and briefly review the data regarding the clinical experience with this kind of anticancer treatment. Based on recent insights in the various mechanisms of action, we will try to predict the potential new developments of metronomic chemotherapy in oncology.</p>","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"23 2","pages":"143-51"},"PeriodicalIF":0.0000,"publicationDate":"2010-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug news & perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dnp.2010.23.2.1475913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

Angiogenesis is crucial for the growth of cancer. As such, it has become an established target to fight cancer. Metronomic chemotherapy-the chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule of administration, at close regular intervals, with no prolonged drug-free breaks-is a potential approach to control advanced cancer disease. It is thought to work primarily through antiangiogenic mechanisms and has the property to kill resistant cancer cells and/or to inhibit tumor growth while significantly reducing undesirable toxic side effects. Here, we will discuss potential mechanisms of action of metronomic chemotherapy and briefly review the data regarding the clinical experience with this kind of anticancer treatment. Based on recent insights in the various mechanisms of action, we will try to predict the potential new developments of metronomic chemotherapy in oncology.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
节拍化疗:回到未来!
血管生成对癌症的生长至关重要。因此,它已成为对抗癌症的既定目标。节律化疗是一种以相对较低的、毒性最小的剂量、频繁给药的慢性化疗,间隔很近,没有长时间的无药中断,是一种控制晚期癌症疾病的潜在方法。它被认为主要通过抗血管生成机制起作用,具有杀死耐药癌细胞和/或抑制肿瘤生长的特性,同时显著减少不良毒副作用。在这里,我们将讨论节律化疗的潜在作用机制,并简要回顾有关这种抗癌治疗的临床经验。基于对各种作用机制的最新见解,我们将尝试预测肿瘤节律化疗的潜在新发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug news & perspectives
Drug news & perspectives 医学-药学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Osteopontin. Trends in medicinal chemistry. Molecule of the Month. The significance of GlgE as a new target for tuberculosis. Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1